Literature DB >> 12804634

Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome.

David P Steensma1, Ayalew Tefferi, Chin-Yang Li.   

Abstract

The syndrome of chronic myelomonocytic leukemia (CMML) includes a heterogeneous group of patients who exhibit both myelodysplastic and myeloproliferative clinicopathological features. Troublesome splenomegaly is uncommon in myelodysplastic syndrome (MDS), but when organomegaly occurs, this complication is more likely to be associated with myelodysplastic-myeloproliferative overlap syndromes such as CMML rather than "dysplasia-only" MDS types such as refractory anemia. We report a single-institution experience with splenectomy in CMML patients, including a detailed review of splenic histopathology. Twelve patients with CMML underwent splenectomy at the Mayo Clinic, primarily because of refractory thrombocytopenia and/or mechanical complications related to splenomegaly. Three of the 12 patients (25%) died as a direct result of surgery, and significant postoperative morbidity was seen in another 4 patients (33%). Thrombocytopenia improved in 4 of the 11 patients (36%) with low platelet counts before surgery. Three of the four responders had an abundance of CD68 (PGM1)-positive foamy histiocytes in the marginal zone surrounding the splenic white pulp-a pattern which can be seen in immune thrombocytopenia-and two of these three patients had thrombocytopenia out of proportion to the degree of anemia pre-operatively, suggestive of peripheral destruction of platelets. More consistent splenic pathological findings in the 12 patients included trilineage extramedullary hematopoiesis in splenic red pulp and expansion of splenic cords by a myelomonocytic infiltrate. This study underscores both the uniformity and diversity of splenic findings in CMML, highlights the potential dangers and benefits of splenectomy in this group, and suggests peripheral destruction of platelets as a mechanism contributing to thrombocytopenia in a subset of CMML patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804634     DOI: 10.1016/s0145-2126(03)00006-7

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  8 in total

1.  Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.

Authors:  Benjamin S Braun; Joehleen A Archard; Jessica A G Van Ziffle; David A Tuveson; Tyler E Jacks; Kevin Shannon
Journal:  Blood       Date:  2006-05-23       Impact factor: 22.113

2.  Fusion of platelet-derived growth factor receptor β to CEV14 gene in chronic myelomonocytic leukemia: A case report and review of the literature.

Authors:  Sheng-Lan Gong; Meng-Qiao Guo; Gu-Sheng Tang; Chun-Ling Zhang; Hui-Ying Qiu; Xiao-Xia Hu; Jian-Min Yang
Journal:  Oncol Lett       Date:  2015-11-18       Impact factor: 2.967

Review 3.  Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors.

Authors:  David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

4.  Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms.

Authors:  Agnes Fütterer; Miguel R Campanero; Esther Leonardo; Luis M Criado; Juana M Flores; Jesús M Hernández; Jesús F San Miguel; Carlos Martínez-A
Journal:  J Clin Invest       Date:  2005-08-25       Impact factor: 14.808

5.  Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients.

Authors:  Prateek Pophali; Pedro Horna; Terra L Lasho; Christy M Finke; Rhett P Ketterling; Naseema Gangat; David Nagorney; Ayalew Tefferi; Mrinal M Patnaik
Journal:  Am J Hematol       Date:  2018-10-05       Impact factor: 10.047

6.  Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression.

Authors:  Kseniya Petrova-Drus; April Chiu; Elizabeth Margolskee; Sharon Barouk-Fox; Julia Geyer; Ahmet Dogan; Attilio Orazi
Journal:  Oncotarget       Date:  2017-10-17

7.  Spontaneous splenic rupture - An uncommon complication of chronic myelomonocytic leukemia.

Authors:  Abdul Muqtadir Abbasi; Salman Adil; Bushra Moiz
Journal:  Leuk Res Rep       Date:  2020-05-29

8.  Atraumatic Splenic Rupture due to Chronic Myelomonocytic Leukemia Treated with Partial Splenic Artery Embolization.

Authors:  Yunan Nie; Andrew Kent; Minh Do; Maria Amaya; Catherine Klein; Christiane Thienelt
Journal:  Case Rep Oncol       Date:  2022-03-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.